Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2850232 | American Heart Journal | 2011 | 10 Pages |
Abstract
In HF patients with chronic postinfarction cardiomyopathy, transcatheter administration of myoblasts in doses of 400 to 800 million cells is feasible and may lead to important clinical benefits. Ventricular tachycardia may be provoked by myoblast injection but appears to be a transient and treatable problem. A large-scale outcome trial of myoblast administration in HF patients with postinfarction cardiomyopathy is feasible and warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Thomas J. MD, PhD, FACC, Christopher M. MD, FACC, Timothy MD, FACC, Andrew MD, FACC, Dean J. MD, FACC, F. David MD, FACC, Alan MD, FACC, Richard MD, FACC, Richard JD, Douglas RN, Missy BA, Diane BS, Rhonda MSPH, John H. MD, MHS, FACC, Warren MD, FACC,